# An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures

> **NCT00372528** · PHASE3 · TERMINATED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 21 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** pregabalin (LYRICA)

## Key facts

- **NCT ID:** NCT00372528
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** This study was terminated on April 8, 2011 as Pfizer Canada could no longer supply study drug. No efficacy or safety concerns factored into this decision.
- **Last updated:** 2021-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00372528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00372528, "An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00372528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*